Material Safety Data Sheet
12601 Twinbrook Parkway, Rockville, MD 20852 USA Phone Calls: 301-816-8129 8 a.m. to 5 p.m. EST Mon. - Fri.
ATTENTION !
USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.
PROBENECID
Catalog Number: 1563003 Revision Date: October 16, 2008
SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION
Common Name: Probenecid
Manufacturer: U. S. Pharmacopeia Responsible Party: Reference Standards Technical Services Mailing Address: 12601 Twinbrook Parkway, Rockville, MD 20852 USA Phone: 301-816-8129 Hours: 8 a.m. to 5 p.m. EST Mon. - Fri. Product Use: USP Reference Standards and Authentic Substances are used for chemical tests and assays in analytical, clinical, pharmaceutical, and research laboratories.
SECTION 2 - HAZARD INFORMATION
Adverse Effects: Adverse effects may include headache; dizziness; frequent and painful urge to urinate; painful urination; blood in urine; nausea; vomiting; sore gums; skin rash, hives, or itching; lower back and/or side pain; joint pain, redness, or swelling; loss of appetite; and flushing or redness of face. Possible allergic reaction to material if inhaled, ingested, or in contact with skin. Overdose Effects: Extremely large doses may cause clonic-tonic seizures, severe vomiting, and respiratory failure. Acute: Possible eye, skin, gastrointestinal, and/or respiratory tract irritation. Chronic: Possible hypersensitization. Medical Conditions Aggravated by Exposure: Hypersensitivity to material, gout, peptic ulcer, blood dyscrasias, uric acid kidney stones or history of, cancer chemotherapy with rapidly cytolytic antineoplastic agents, radiation therapy, porphyria, kidney function impairment or disease, and urate nephropathy or history of. Cross Sensitivity: n/f Target Organs: Kidneys and central nervous system For additional information on toxicity, see Section 11.
SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS
Common Name: Probenecid Copyright 2008 The United States Pharmacopeial Convention, Inc. All Rights Reserved. n/f = not found Page 1 of 5
PROBENECID
Catalog Number: 1563003 Formula: C13H19NO4S Synonym: n/f Chemical Name: Benzoic acid, 4-[(dipropylamino)sulfonyl]CAS: 57-66-9 RTECS Number: DG9400000 Chemical Family: Benzoic acid derivative (sulfonamide) Therapeutic Category: Uricosuric Composition: Pure Material Revision Date: October 16, 2008
SECTION 4 - FIRST AID MEASURES
Inhalation: May cause irritation. Avoid inhalation. Remove to fresh air. Eye: May cause irritation. Avoid contact. Flush with copious quantities of water. Skin: May cause irritation. Flush with copious quantities of water. Ingestion: May cause irritation. Flush out mouth with water. This material is rapidly and well absorbed from the gastrointestinal tract. Duration of effect is about 8 hours. General First Aid Procedures: Remove from exposure. Remove contaminated clothing. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen. Obtain medical attention. Note to Physicians Overdose Treatment: Treatment of probenecid overdose should be symptomatic and supportive and may include the following: 1. Administer activated charcoal as a slurry. 2. Administer an intravenous benzodiazepine such as diazepam or lorazepam. 3. Consider phenobarbital or propofol if seizures recur. 4. Monitor for hypotension, dysrhythmias, respiratory depression, and need for endotracheal intubation. Evaluate for hypoglycemia, electrolyte disturbances, hypoxia. 5. Patients should be observed for possible kidney function abnormalities, or blood dyscrasias. [Poisindex 2008]
SECTION 5 - FIREFIGHTING MEASURES
Extinguisher Media: Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials. Fire and Explosion Hazards: This material is assumed to be combustible. As with all dry powders, it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity. Firefighting Procedures: As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
SECTION 6 - ACCIDENTAL RELEASE MEASURES
Spill Response: Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.
SECTION 7 - HANDLING AND STORAGE
Handling: As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling. Storage: Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.
SECTION 8 - EXPOSURE CONTROL / PERSONAL PROTECTION
Copyright 2008 The United States Pharmacopeial Convention, Inc. All Rights Reserved. n/f = not found Page 2 of 5
PROBENECID
Catalog Number: 1563003 Revision Date: October 16, 2008
Engineering Controls: Engineering controls such as exhaust ventilation are recommended. Respiratory Protection: Use a NIOSH-approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used. Gloves: Chemically compatible Eye Protection: Safety glasses or goggles Protective Clothing: Protect exposed skin. Exposure Limits: n/f
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Properties as indicated on the MSDS are general and not necessarily specific to the USP Reference Standard Lot provided. Appearance and Odor: White or practically white, fine, crystalline powder; practically odorless. Odor Threshold: n/f pH: 5.8 Melting Range: 194 - 202 C Boiling Point: n/f Flash Point: n/f Autoignition Temperature: n/f Evaporation Rate: n/f Upper Flammability Limit: n/f Lower Flammability Limit: n/f Vapor Pressure: n/f Vapor Density: n/f Specific Gravity: n/f Solubility in Water: Practically insoluble Fat Solubility: n/f
Other Solubility: Practically insoluble in dilute acids; soluble in dilute alkali, in chloroform, in alcohol, and in acetone. Partition Coefficient: n-octanol/water: 3.21 Percent Volatile: n/f Reactivity in Water: n/f Explosive Properties: n/f Oxidizing Properties: n/f Formula: C13H19NO4S
Molecular Weight: 285.36
Copyright 2008 The United States Pharmacopeial Convention, Inc. All Rights Reserved.
n/f = not found
Page 3 of 5
PROBENECID
Catalog Number: 1563003 Revision Date: October 16, 2008
SECTION 10 - STABILITY AND REACTIVITY
Conditions to Avoid: Avoid exposure to moisture. Incompatibilities: Strong oxidizers.
Decomposition Products: When heated to decomposition, material emits very toxic fumes of SOx and NOx. Emits toxic fumes under fire conditions. Stable? Yes Hazardous Polymerization? No
SECTION 11 - TOXICOLOGICAL PROPERTIES
Oral Rat: LD50: 1600 mg/kg Oral Mouse: LD50: 1666 mg/kg
Other Toxicity Data: n/f Irritancy Data: Corrosivity: n/f n/f
Sensitization Data: Guinea pig skin sensitization test: non-sensitizing Listed as a Carcinogen by: NTP: No IARC: No OSHA: No
Other Carcinogenicity Data: In two-year studies with rats receiving 100 or 400 mg/kg probenecid there was no evidence of carcinogenic activity. There was no evidence of carcinogenicity in male mice given 100 or 400 mg/kg, although there was an increased incidence of hepatocellular adenomas in female mice. Mutagenicity Data: It was negative for mutagenicity in the Ames S. typhimurium test, with and without activation. It was also negative in the mitotic recombination or gene conversion assay in Saccharomyces cerevisiae, with metabolic activation. In cytogenetic tests with Chinese hamster ovary cells, probenecid induced sister chromatid exchanges in the absence, but not in the presence, of S9 activation. No induction of chromosomal aberrations was observed, with or without S9 activation.
Reproductive and Developmental Effects: Probenecid did not cause adverse reproductive effects in rabbits. No increase in fetal deaths or growth retardation was observed among the offspring of pregnant mice treated with 22 times the maximum human dose of probenecid.
SECTION 12 - ECOLOGICAL INFORMATION
Ecological Information: n/f
SECTION 13 - DISPOSAL CONSIDERATIONS
Disposal: Dispose of waste in accordance with all applicable Federal, State, and local laws.
SECTION 14 -TRANSPORT INFORMATION
Shipping Name: Class: n/f n/f
UN Number: n/f Packing Group: n/f
Additional Transport Information: n/f
SECTION 15 - REGULATORY INFORMATION
U.S. Regulatory Information: n/f
Copyright 2008 The United States Pharmacopeial Convention, Inc. All Rights Reserved.
n/f = not found
Page 4 of 5
PROBENECID
Catalog Number: 1563003 International Regulatory Information: EINECS#: 200-344-3 Hazard code: Xn Risk phrase: R22 Revision Date: October 16, 2008
SECTION 16 - OTHER INFORMATION
Revision: 16-Oct-08 20-Sep-04
Previous Revision Date:
Copyright 2008 The United States Pharmacopeial Convention, Inc. All Rights Reserved.
n/f = not found
Page 5 of 5
